Bill
Bill > SF2322
IA SF2322
IA SF2322A bill for an act relating to insurance coverage for prescription insulin drugs.
summary
Introduced
02/12/2026
02/12/2026
In Committee
02/12/2026
02/12/2026
Crossed Over
Passed
Dead
Introduced Session
91st General Assembly
Bill Summary
This bill relates to prescription insulin drugs and coverage by policies, contracts, or plans providing for third-party payment or prepayment of health or medical expenses that provide coverage for prescription drugs. The bill requires a policy, contract, or plan providing for third-party payment or prepayment of health or medical expenses that provides coverage for prescription drugs to cap the total amount of cost-sharing that a covered person is required to pay per prescription filled of an insulin drug to an amount not more than $35 for an up to 31-day supply of at least one type of rapid-acting prescription insulin drugs, short-acting prescription insulin drugs, intermediate-acting prescription insulin drugs, or long-acting prescription insulin drugs. “Prescription insulin drug” is defined in the bill as a prescription drug that contains insulin, is used to treat diabetes, has been prescribed as medically necessary by a covered person’s health care professional, and is a benefit covered by a covered person’s policy, contract, or plan. The bill defines “cost-sharing” as any coverage limit, copayment, coinsurance, deductible, or other out-of-pocket expense imposed on a covered person. The bill does not prohibit a policy, contract, or plan providing for third-party payment or prepayment of health or medical expenses from reducing a covered person’s cost-sharing to less than $35 for up to a 31-day supply of a prescription insulin drug. The bill applies to third-party payment provider contracts, policies, or plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2027, by the third-party payment providers enumerated in the bill. The bill specifies the types of specialized health-related insurance which are not subject to the coverage requirements of the bill. The commissioner of insurance may adopt rules to administer the bill.
AI Summary
This bill requires insurance policies, contracts, or plans that cover prescription drugs to cap the amount a person has to pay out-of-pocket for a prescription insulin drug to no more than $35 for a 31-day supply, starting January 1, 2027. "Cost-sharing" refers to any deductible, copayment, coinsurance, or other out-of-pocket expense. A "prescription insulin drug" is defined as a prescribed insulin medication deemed medically necessary by a healthcare professional for treating diabetes and covered by the insurance plan. The bill specifies that this cap applies to various types of insulin, including rapid-acting, short-acting, intermediate-acting, and long-acting forms, and does not prevent insurers from offering even lower cost-sharing amounts. Certain types of specialized health insurance, such as dental, vision, or accident-only coverage, are exempt from these requirements, and the state's commissioner of insurance is authorized to create rules to implement the bill.
Committee Categories
Business and Industry
Sponsors (1)
Last Action
Subcommittee: Warme, Dickey, and Drey. S.J. 331. (on 02/19/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.legis.iowa.gov/legislation/BillBook?ga=91&ba=SF2322 |
| BillText | https://www.legis.iowa.gov/docs/publications/LGI/91/attachments/SF2322.html |
Loading...